Stocks News

LAST PRICE
135.0800
TODAY'S CHANGE (%)
Trending Up1.4600 (1.0927%)

Bid / Lots
134.1600/ 1
Ask / Lots
136.5000/ 4
Open / Previous Close
133.6200 / 133.6200
Day Range
Low 133.6200
High 136.0000
52 Week Range
Low 93.0200
High 148.3699
Volume
915,290
average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Jun 12, 2024
- DJ Neurocrine Is Maintained at Overweight by Morgan Stanley, from 1:14PM ET on Wednesday Jun 12, 2024 by Dow Jones
  1:14PM ET on Wednesday Jun 12, 2024 by Dow Jones
  Companies Mentioned: NBIX
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/NBIX/analyst-ratings
  
  (END) Dow Jones Newswires
  
  June 12, 2024 13:14 ET (17:14 GMT)
Jun 3, 2024
- Neurocrine Biosciences Presented CAHtalyst(TM) Phase 3 Pediatric and Adult Studies, CAHtalog(TM) Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024, from 8:01AM ET on Monday Jun 03, 2024 by Dow Jones
  8:01AM ET on Monday Jun 03, 2024 by Dow Jones
  Companies Mentioned: NBIX
  
  Neurocrine Biosciences Presented CAHtalyst(TM) Phase 3 Pediatric and Adult Studies, CAHtalog(TM) Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024
- Neurocrine Biosciences Announces Publication of Primary CAHtalyst(TM) Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine, from 7:35AM ET on Monday Jun 03, 2024 by Dow Jones
  7:35AM ET on Monday Jun 03, 2024 by Dow Jones
  Companies Mentioned: NBIX
  
  Neurocrine Biosciences Announces Publication of Primary CAHtalyst(TM) Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
- Neurocrine Biosciences Announces Publication of Primary CAHtalyst(TM) Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine, from 7:30AM ET on Monday Jun 03, 2024 by Dow Jones
  7:30AM ET on Monday Jun 03, 2024 by Dow Jones
  Companies Mentioned: NBIX
  
  Neurocrine Biosciences Announces Publication of Primary CAHtalyst(TM) Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
May 31, 2024
- Neurocrine Biosciences Insider Sold Shares Worth $5,338,565, According to a Recent SEC Filing, from 3:49AM ET on Friday May 31, 2024 by MT Newswires
  3:49AM ET on Friday May 31, 2024 by MT Newswires
  Companies Mentioned: NBIX
  03:49 AM EDT, 05/31/2024 (MT Newswires) -- Stephen A Sherwin, Director, on May 29, 2024, sold 40,000 shares in Neurocrine Biosciences (NBIX) for $5,338,565. Following the Form 4 filing with the SEC, Sherwin has control over a total of 26,504 shares ...

Today
- Tempus, United Therapeutics Launch Collaboration to Use AI to Detect Risk of Pulmonary Hypertension, from 8 hours ago by MT Newswires
  8 hours ago by MT Newswires
  Companies Mentioned: UTHR, TEM
Jun 18, 2024
- --UBS Raises Qiagen Price Target to $46 From $44, Maintains Neutral Rating, from 10:52AM ET on Tuesday Jun 18, 2024 by MT Newswires
  10:52AM ET on Tuesday Jun 18, 2024 by MT Newswires
  Companies Mentioned: QGEN
- JPMorgan Raises Price Target on Qiagen to $54 From $52, Maintains Overweight Rating, from 10:19AM ET on Tuesday Jun 18, 2024 by MT Newswires
  10:19AM ET on Tuesday Jun 18, 2024 by MT Newswires
  Companies Mentioned: QGEN
Jun 17, 2024
- United Therapeutics Insider Sold Shares Worth $1,033,984, According to a Recent SEC Filing, from 4:36PM ET on Monday Jun 17, 2024 by MT Newswires
  4:36PM ET on Monday Jun 17, 2024 by MT Newswires
  Companies Mentioned: UTHR
- Qiagen Targets 7% Annual Sales Growth Through 2028, from 8:41AM ET on Monday Jun 17, 2024 by MT Newswires
  8:41AM ET on Monday Jun 17, 2024 by MT Newswires
  Companies Mentioned: QGEN
Jun 14, 2024
- United Therapeutics Insider Sold Shares Worth $1,027,716, According to a Recent SEC Filing, from 4:37PM ET on Friday Jun 14, 2024 by MT Newswires
  4:37PM ET on Friday Jun 14, 2024 by MT Newswires
  Companies Mentioned: UTHR
Jun 12, 2024
- Wells Fargo Raises Price Target on United Therapeutics to $350 From $325, Maintains Overweight Rating, from 9:17AM ET on Wednesday Jun 12, 2024 by MT Newswires
  9:17AM ET on Wednesday Jun 12, 2024 by MT Newswires
  Companies Mentioned: UTHR
Jun 10, 2024
- KKR & Co, CrowdStrike, GoDaddy to Join S&P 500 Index on June 24, from 6:38AM ET on Monday Jun 10, 2024 by MT Newswires
  6:38AM ET on Monday Jun 10, 2024 by MT Newswires
  Companies Mentioned: IART, ILMN, LEG, MCS, MED, MEI, OSUR, PENN, CLDT, RBA, RGP, RHI, KKR, TDW, TPL, TTEC, WERN, ADTN, KRYS, ALTR, WHD, ATNI, HOUS, CRWD, GO, CRNC, WMG, STEP, BMRN, HTZ, XPER, CMA, NXT, GDDY, VIRT, NFBK
Jun 7, 2024
- Medpace Holdings Insider Sold Shares Worth $3,081,617, According to a Recent SEC Filing, from 4:21PM ET on Friday Jun 07, 2024 by MT Newswires
  4:21PM ET on Friday Jun 07, 2024 by MT Newswires
  Companies Mentioned: MEDP
- BioMarin Pharmaceutical Reports New Data Affirming Long-Term Safety, Efficacy of Roctavian, from 10:25AM ET on Friday Jun 07, 2024 by MT Newswires
  10:25AM ET on Friday Jun 07, 2024 by MT Newswires
  Companies Mentioned: BMRN

Neurocrine Biosciences Inc
NASDAQ:NBIXUnited States

Search Criteria

Jun 12, 2024

DJ Neurocrine Is Maintained at Overweight by Morgan Stanley, from 1:14PM ET on Wednesday Jun 12, 2024 by Dow Jones

Jun 3, 2024

Neurocrine Biosciences Presented CAHtalyst(TM) Phase 3 Pediatric and Adult Studies, CAHtalog(TM) Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024, from 8:01AM ET on Monday Jun 03, 2024 by Dow Jones

Neurocrine Biosciences Announces Publication of Primary CAHtalyst(TM) Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine, from 7:35AM ET on Monday Jun 03, 2024 by Dow Jones

Neurocrine Biosciences Announces Publication of Primary CAHtalyst(TM) Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine, from 7:30AM ET on Monday Jun 03, 2024 by Dow Jones

May 31, 2024

Neurocrine Biosciences Insider Sold Shares Worth $5,338,565, According to a Recent SEC Filing, from 3:49AM ET on Friday May 31, 2024 by MT Newswires

Peers Headlines

Today

Tempus, United Therapeutics Launch Collaboration to Use AI to Detect Risk of Pulmonary Hypertension, from 8 hours ago by MT Newswires

Jun 18, 2024

--UBS Raises Qiagen Price Target to $46 From $44, Maintains Neutral Rating, from 10:52AM ET on Tuesday Jun 18, 2024 by MT Newswires

JPMorgan Raises Price Target on Qiagen to $54 From $52, Maintains Overweight Rating, from 10:19AM ET on Tuesday Jun 18, 2024 by MT Newswires

Jun 17, 2024

United Therapeutics Insider Sold Shares Worth $1,033,984, According to a Recent SEC Filing, from 4:36PM ET on Monday Jun 17, 2024 by MT Newswires

Qiagen Targets 7% Annual Sales Growth Through 2028, from 8:41AM ET on Monday Jun 17, 2024 by MT Newswires

Jun 14, 2024

United Therapeutics Insider Sold Shares Worth $1,027,716, According to a Recent SEC Filing, from 4:37PM ET on Friday Jun 14, 2024 by MT Newswires

Jun 12, 2024

Wells Fargo Raises Price Target on United Therapeutics to $350 From $325, Maintains Overweight Rating, from 9:17AM ET on Wednesday Jun 12, 2024 by MT Newswires

Jun 10, 2024

KKR & Co, CrowdStrike, GoDaddy to Join S&P 500 Index on June 24, from 6:38AM ET on Monday Jun 10, 2024 by MT Newswires

Jun 7, 2024

Medpace Holdings Insider Sold Shares Worth $3,081,617, According to a Recent SEC Filing, from 4:21PM ET on Friday Jun 07, 2024 by MT Newswires

BioMarin Pharmaceutical Reports New Data Affirming Long-Term Safety, Efficacy of Roctavian, from 10:25AM ET on Friday Jun 07, 2024 by MT Newswires